A series of new 3-substituted-7-(2-chloro-6-ethoxypyridin-4-yl)-9-(2,4-dichlorophenyl)-2- methylpyrido[3,2:4,5]thieno[3,2-d]pyrimidin-4(3H)-one derivatives (3-10) were synthesized using 7-(2-chloro-6-ethoxypyridin-4-yl)-9-(aryl)-2-methyl-4H-pyrido-[3,2:4,5]thieno[3,2-d]-[1,3]oxazin-4-one (2a,b) as a starting material. All the newly synthesized compounds were evaluated for their antimicrobial activities. The antimicrobial screening showed that many of these obtained compounds have good antimicrobial activities comparable to streptomycin and fusidic acid as reference drugs. Also, the pharmacological screening showed that many compounds have good analgesic and antiparkinsonian activities comparable to Valdecoxib® and Benzotropine® as reference drugs. The structures of newly synthesized compounds were confirmed by IR, 1H NMR, 13C NMR, MS spectral data and elemental analysis.
一系列新的3-取代-7-(
2-氯-6-乙氧基吡啶-4-基)-9-(2,4-二
氯苯基)-2-
甲基吡啶并[3,2:4,5]
噻吩并[3,2-d]
嘧啶-4(3H)-酮衍
生物(3-10)是以7-(
2-氯-6-乙氧基吡啶-4-基)-9-(芳基)-2-甲基-4H-
吡啶并[3,2:4,5]
噻吩并[3,2-d]-[1,3]噁嗪-4-酮(2a,b)为起始原料合成的。所有新合成的化合物都经过抗微
生物活性评估。抗微
生物筛选显示,这些获得的化合物中有许多具有与
链霉素和
夫西地酸相当的良好抗微
生物活性。此外,药理筛选表明,许多化合物具有与
伐地考昔(Valdecoxib®)和苯
托品(Benzotropine®)相当的良好镇痛和抗帕
金森病活性。新合成化合物的结构通过IR、1H NMR、13C NMR、MS光谱数据和元素分析得到确认。